SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Biocon redeems commercial papers of Rs 2,250 crore

23 Feb 2023 Evaluate

Biocon has fulfilled its payment obligation and has fully redeemed the Commercial Papers (CPs) of Rs 2,250 crore. The maturity date of the said commercial papers was February 22, 2023 and the payment made on the same date.

Earlier, the company had raised Rs 1070 crore through allotment of 1,07,000 unlisted, secured, rated, redeemable, non-convertible debentures (NCDs) of face value of Rs 1,00,000 each on private placement basis in 3 series.

Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.

Biocon Share Price

380.55 -2.05 (-0.54%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×